Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Patients in higher BMI categories or with more complex metabolic conditions are usually directed to tirzepatide for its higher average magnitude
PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177 Lu-labeled PSMA-617
With ongoing medical monitoring, each patients treatment is adjusted based on goals, response, and overall wellness to help promote safe and sustainable weight loss
10.1038/sj.ejcn.1602109
US$ 21.79
US$ 29.89
US$ 22.07
